Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.675
Bid: 1.65
Ask: 1.70
Change: -0.125 (-6.94%)
Spread: 0.05 (3.03%)
Open: 1.825
High: 1.875
Low: 1.675
Prev. Close: 1.80
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

30 Nov 2007 16:23

EpiStem Holdings plc30 November 2007 Total Voting Rights 30 November 2007 EpiStem Holdings plc ("EpiStem" or the "Company") In conformity with the Disclosure and Transparency Rule 5.6.1, the Company notifies the market of the following: As at the date of this announcement, the Company's issued share capital consistsof 7,191,883 ordinary shares with a nominal value of 1.5 pence each ("OrdinaryShares"), with voting rights. The Company does not hold any Ordinary Shares inTreasury. Therefore, the total number of Ordinary Shares with voting rights is 7,191,883. The above figure of 7,191,883 Ordinary Shares may be used by shareholders in theCompany as the denominator for the calculations by which they will determine ifthey are required to notify their interest in, or a change in their interest in,the share capital of the Company under the FSA's Disclosure and TransparencyRules. For further information please contact: Matthew WallsCEO Epistem Holdings PlcTel: +44 (0)161 606 7258 Thilo Hoffman or Simon BrownLandsbanki Securities (UK) LimitedTel: +44 (0)207 426 9000 Mike Wort or Anna DumphyMC Bio-Communication LimitedTel: +44 (0)207 744 7711 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Jun 202312:25 pmRNSEquity Prepayment Facility drawdown
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension
30th Mar 20237:00 amRNSPositive final recommendation by NICE
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
20th Mar 20237:00 amRNSCommence of roll out in Greater Manchester
9th Feb 20232:05 pmRNSSecond Price Monitoring Extn
9th Feb 20232:00 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSAIHL test preliminary recommendation by NICE
27th Jan 20232:05 pmRNSSecond Price Monitoring Extn
27th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
25th Jan 20234:40 pmRNSSecond Price Monitoring Extn
25th Jan 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20234:40 pmRNSSecond Price Monitoring Extn
19th Jan 20234:35 pmRNSPrice Monitoring Extension
29th Dec 20226:10 pmRNSResult of AGM
5th Dec 20227:00 amRNSNotice of AGM
30th Nov 20227:00 amRNSBlock Listing Six Monthly Return
21st Nov 20227:00 amRNSAudited Final Results
14th Nov 20227:00 amRNSNotice of Results
24th Oct 20227:00 amRNSGrant of options
5th Oct 20224:40 pmRNSSecond Price Monitoring Extn
5th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSUS FDA pre-submission for Genedrive MT-RNR1 kit
26th Sep 20227:00 amRNSNICE to accelerate evaluation of Genedrive test
22nd Aug 20227:00 amRNSNICE includes CYP2C19-ID Kit in new programme
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:00 pmRNSPrice Monitoring Extension
16th Jun 20227:00 amRNSNICE to evaluate the Genedrive® MT-RNR1 Test
30th May 20229:05 amRNSSecond Price Monitoring Extn
30th May 20229:00 amRNSPrice Monitoring Extension
30th May 20227:00 amRNSPoint-of-Care COV19-ID Kit receives CTDA approval
27th May 20227:00 amRNSBlock listing Interim Review
25th Apr 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.